股本结构
单位：万股
| 公告日期 | 2025-11-12 | 2025-11-13 | 2025-11-13 | 2025-08-29 | 2025-08-13 | 2025-05-27 |
|---|---|---|---|---|---|---|
| 证券总股本 | 5276.65 | 4898.03 | 4770.54 | 4702.55 | 4663.34 | 4571.00 |
| 普通股本 | 5276.65 | 4898.03 | 4770.54 | 4702.55 | 4663.34 | 4571.00 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-12 | 2025-11-06 | 2025-09-30 | 2025-08-27 | 2025-06-30 | 2025-05-07 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-12 | 5276.65 | 未披露 |
更多>>
Common Stock offered 5,741,000 shares by the company
|
2025-11-12 |
| 2025-11-13 | 4898.03 | 未披露 | 定期报告 | 2025-11-06 |
| 2025-11-13 | 4770.54 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuances of common stock from the Sales Agreement, net
|
2025-09-30 |
| 2025-08-29 | 4702.55 | 未披露 | 定期报告 | 2025-08-27 |
| 2025-08-13 | 4663.34 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuances of common stock from the Sales Agreement, net
Exercise of pre-funded warrants
|
2025-06-30 |
| 2025-05-27 | 4571.00 | 未披露 | 定期报告 | 2025-05-07 |
| 2025-04-29 | 4567.29 | 未披露 | 定期报告 | 2025-04-17 |
| 2025-05-14 | 4544.59 | 未披露 |
更多>>
From January 1, 2025 to March 31, 2025
Issuance of common stock for consulting agreement
Exercise of pre-funded warrants
Issuances of common stock from the Sales Agreement, net
Issuances of common stock, net of issuance costs
|
2025-03-31 |
| 2025-03-27 | 4539.59 | 未披露 | 定期报告 | 2025-03-20 |
| 2025-02-28 | 4458.95 | 未披露 |
更多>>
Common stock offered 6,396,787 shares by the company
|
2025-02-28 |
| 2025-02-28 | 3819.27 | 未披露 | 定期报告 | 2025-02-26 |
| 2025-03-27 | 3798.74 | 未披露 |
更多>>
From September 30, 2024 to December 31, 2024
Issuances of common stock, from exercise of stock options
Issuances of common stock from the Sales Agreement, net
|
2024-12-31 |
| 2024-11-14 | 3740.91 | 未披露 | 定期报告 | 2024-11-07 |
| 2024-08-13 | 3681.98 | 未披露 | 定期报告 | 2024-08-06 |
| 2024-08-13 | 3677.93 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuances of common stock for consulting agreement
|
2024-06-30 |
| 2024-03-28 | 3667.93 | 未披露 | 定期报告 | 2024-03-21 |
| 2024-03-28 | 3309.45 | 未披露 |
更多>>
From September 30, 2023 to December 31, 2023
Issuance of common stock for consulting agreement
Issuance of common stock from the Sales Agreement, net
Issuances of common stock, from exercise of stock options
|
2023-12-31 |
| 2023-11-14 | 3110.78 | 未披露 | 定期报告 | 2023-11-07 |
| 2023-11-14 | 3100.78 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuances of common stock from the Sales Agreement, net
|
2023-09-30 |
| 2023-08-14 | 3086.82 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuances of common stock, from exercise of stock options
Issuance of common stock for consulting agreement
Issuances of common stock from the Sales Agreement, net
|
2023-06-30 |
| 2023-04-28 | 3082.36 | 未披露 | 定期报告 | 2023-04-27 |
| 2023-03-28 | 3072.36 | 未披露 | 定期报告 | 2023-03-21 |
| 2023-03-28 | 3017.03 | 未披露 |
更多>>
From September 30, 2022 to December 31, 2022
Issuance of common stock for licensing agreement
Issuances of common stock, from exercise of stock options
Issuance of common stock from ATM
Net shares for settlements of equity awards and taxes
|
2022-12-31 |
| 2022-11-14 | 2850.87 | 未披露 | 定期报告 | 2022-11-07 |
| 2022-08-24 | 2845.87 | 未披露 | 定期报告 | 2022-08-18 |
| 2022-08-08 | 2845.87 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuances of common stock, from exercise of stock options
|
2022-06-30 |
| 2022-05-11 | 2845.09 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock from exercise of stock options
|
2022-03-31 |
| 2022-03-31 | 2844.86 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock, net of issuance costs
Issuance of common stock, from exercise of stock options
Issuance of common stock from 401K match
|
2021-12-31 |
| 2021-12-16 | 2843.79 | 未披露 | 定期报告 | 2021-11-29 |
| 2021-11-10 | 2843.51 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock, from exercise of stock options
|
2021-09-30 |
| 2021-08-12 | 2842.38 | 未披露 | 定期报告 | 2021-08-06 |
| 2021-08-12 | 2841.79 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock, from exercise of stock options
Issuance of common stock, net of issuance costs
|
2021-06-30 |
| 2021-06-17 | 2757.24 | 未披露 |
更多>>
1.Common stock offered 5,294,118 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 22,278,261 shares of common stock outstanding as of March 31, 2021.
|
2021-06-17 |
| 2021-05-13 | 2227.83 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Issuance of common stock from 401K match
|
2021-03-31 |
| 2020-11-13 | 2226.16 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock, net of issuance costs
|
2020-09-30 |
| 2020-08-13 | 2135.04 | 未披露 |
更多>>
1.Common stock offered by the company 6,000,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 15,350,445 shares of common stock outstanding as of March 31, 2020.
|
2020-08-13 |
| 2020-05-13 | 1536.16 | 未披露 | 定期报告 | 2020-05-07 |
| 2020-07-22 | 1535.04 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of common stock, net of issuance costs
Issuance of common stock for warrant exercise
Issuance of common stock from 401K match
|
2020-03-31 |
| 2020-03-27 | 1528.52 | 未披露 | 定期报告 | 2020-03-09 |
| 2020-02-14 | 1450.96 | 未披露 |
更多>>
1.Common Stock Offered by Us 9,230,770 shares.
2.The number of shares of our common stock to be outstanding after this offering is based on 5,278,850 shares of common stock outstanding as of September 30, 2019
|
2020-02-14 |
| 2020-03-27 | 528.12 | 未披露 |
更多>>
from December 31, 2018 to December 10, 2019
Issuance of common stock, net of issuance costs
Issuance of common stock for antidilution
Issuance of common stock for convertible debt
Issuance of common stock from equity transaction
Equity from merger transaction
Issuance of common stock from 401K match
|
2019-12-10 |
| 2019-11-07 | 577.89 | 未披露 | 定期报告 | 2019-10-31 |
| 2019-11-07 | 527.89 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of common stock from 401K match
Issuance of common stock from equity transaction
|
2019-09-30 |
| 2019-08-16 | 527.89 | 未披露 | 定期报告 | 2019-08-13 |
| 2019-08-01 | 517.75 | 未披露 |
更多>>
from March 31, 2019 to May 8, 2019
Issuance of common stock from 401K match
|
2019-05-08 |
| 2019-05-14 | 517.29 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of common stock, net of issuance costs
Issuance of common stock for antidilution
Issuance of common stock for convertible debt
Equity from merger transaction
|
2019-03-31 |
| 2019-03-18 | 534.82 | 未披露 |
更多>>
In connection with the closing of the merger, Edge effected a 20-1 reverse split of its common stock. Shares of the combined company's common stock will begin trading on a split-adjusted basis under the new ticker symbol on the Nasdaq Capital Market on March 18, 2019. Immediately following the completion of the merger and the reverse stock split, the total number of issued and outstanding shares of the combined company's common stock will be 5,348,174, with pre-merger PDS Biotechnology stockholders collectively owning approximately 70% of the issued and outstanding common stock of the combined company and pre-merger Edge stockholders owning approximately 30% of the issued and outstanding common stock of the combined company.
|
2019-03-18 |
| 2019-02-21 | 3150.98 | 未披露 | 定期报告 | 2019-02-14 |
| 2019-02-21 | 3145.00 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock from exercise of stock options
Issuance of common stock from exercise of warrants
Issuance of common stock from vesting of RSUs
Issuance of common stock from 401K match
|
2018-12-31 |
| 2018-08-01 | 3132.81 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-01 | 3124.62 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-01 | 3086.92 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of common stock, net of issuance costs
Issuance of common stock from exercise of stock options
Issuance of common stock from exercise of warrants
Issuance of common stock from 401K match
|
2017-12-31 |
| 2017-11-01 | 3085.92 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-01 | 3085.18 | 未披露 | 定期报告 | 2017-07-25 |
| 2017-08-01 | 3082.93 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-04-28 | 3081.14 | 未披露 | 定期报告 | 2017-04-21 |
| 2017-05-03 | 2901.14 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-02 | 2900.99 | 未披露 | 定期报告 | 2017-02-24 |
| 2017-03-02 | 2891.85 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Issuance of common stock from exercise of stock options
Issuance of common stock from exercise of warrants
|
2016-12-31 |
| 2016-11-01 | 2891.74 | 未披露 | 定期报告 | 2016-10-28 |
| 2016-10-21 | 2891.52 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-03 | 2889.86 | 未披露 | 定期报告 | 2016-07-28 |
| 2016-08-03 | 2884.94 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-04-28 | 2881.43 | 未披露 | 定期报告 | 2016-04-25 |
| 2016-03-08 | 2881.32 | 未披露 | 定期报告 | 2016-02-29 |
| 2016-03-08 | 2881.08 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Conversion of Preferred Stock to Common Stock upon initial public offering
Initial public offering of common stock, net of issuance costs
Issuance of common stock from exercise of stock options
Issuance of common stock from exercise of warrants
|
2015-12-31 |
| 2015-11-06 | 2881.08 | 未披露 | 定期报告 | 2015-10-31 |
| 2015-10-02 | 2749.64 | 未披露 | 定期报告 | 2015-10-01 |
| 2015-11-06 | 168.85 | 2396.88 | 定期报告 | 2015-09-30 |
| 2015-08-14 | 231.00 | 2396.88 |
更多>>
from December 31, 2014 to June 30, 2015
Issuance of Series C-2 Preferred Stock, net of issuance costs of $3,782,650
Dividend Series C Preferred Stock
Dividend Series C-1 Preferred Stock
Dividend Series C-2 Preferred Stock
|
2015-06-30 |
Common Stock offered 5,741,000 shares by the company
From June 30, 2025 to September 30, 2025
Issuances of common stock from the Sales Agreement, net
From March 31, 2025 to June 30, 2025
Issuances of common stock from the Sales Agreement, net
Exercise of pre-funded warrants
From January 1, 2025 to March 31, 2025
Issuance of common stock for consulting agreement
Exercise of pre-funded warrants
Issuances of common stock from the Sales Agreement, net
Issuances of common stock, net of issuance costs
Common stock offered 6,396,787 shares by the company
From September 30, 2024 to December 31, 2024
Issuances of common stock, from exercise of stock options
Issuances of common stock from the Sales Agreement, net
From March 31, 2024 to June 30, 2024
Issuances of common stock for consulting agreement
From September 30, 2023 to December 31, 2023
Issuance of common stock for consulting agreement
Issuance of common stock from the Sales Agreement, net
Issuances of common stock, from exercise of stock options
From June 30, 2023 to September 30, 2023
Issuances of common stock from the Sales Agreement, net
From March 31, 2023 to June 30, 2023
Issuances of common stock, from exercise of stock options
Issuance of common stock for consulting agreement
Issuances of common stock from the Sales Agreement, net
From September 30, 2022 to December 31, 2022
Issuance of common stock for licensing agreement
Issuances of common stock, from exercise of stock options
Issuance of common stock from ATM
Net shares for settlements of equity awards and taxes
From March 31, 2022 to June 30, 2022
Issuances of common stock, from exercise of stock options
From December 31, 2021 to March 31, 2022
Issuance of common stock from exercise of stock options
From December 31, 2020 to December 31, 2021
Issuance of common stock, net of issuance costs
Issuance of common stock, from exercise of stock options
Issuance of common stock from 401K match
From June 30, 2021 to September 30, 2021
Issuance of common stock, from exercise of stock options
From March 31, 2021 to June 30, 2021
Issuance of common stock, from exercise of stock options
Issuance of common stock, net of issuance costs
1.Common stock offered 5,294,118 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 22,278,261 shares of common stock outstanding as of March 31, 2021.
From December 31, 2020 to March 31, 2021
Issuance of common stock from 401K match
From June 30, 2020 to September 30, 2020
Issuance of common stock, net of issuance costs
1.Common stock offered by the company 6,000,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 15,350,445 shares of common stock outstanding as of March 31, 2020.
From December 31, 2019 to March 31, 2020
Issuance of common stock, net of issuance costs
Issuance of common stock for warrant exercise
Issuance of common stock from 401K match
1.Common Stock Offered by Us 9,230,770 shares.
2.The number of shares of our common stock to be outstanding after this offering is based on 5,278,850 shares of common stock outstanding as of September 30, 2019
from December 31, 2018 to December 10, 2019
Issuance of common stock, net of issuance costs
Issuance of common stock for antidilution
Issuance of common stock for convertible debt
Issuance of common stock from equity transaction
Equity from merger transaction
Issuance of common stock from 401K match
from June 30, 2019 to September 30, 2019
Issuance of common stock from 401K match
Issuance of common stock from equity transaction
from March 31, 2019 to May 8, 2019
Issuance of common stock from 401K match
from December 31, 2018 to March 31, 2019
Issuance of common stock, net of issuance costs
Issuance of common stock for antidilution
Issuance of common stock for convertible debt
Equity from merger transaction
In connection with the closing of the merger, Edge effected a 20-1 reverse split of its common stock. Shares of the combined company's common stock will begin trading on a split-adjusted basis under the new ticker symbol on the Nasdaq Capital Market on March 18, 2019. Immediately following the completion of the merger and the reverse stock split, the total number of issued and outstanding shares of the combined company's common stock will be 5,348,174, with pre-merger PDS Biotechnology stockholders collectively owning approximately 70% of the issued and outstanding common stock of the combined company and pre-merger Edge stockholders owning approximately 30% of the issued and outstanding common stock of the combined company.
from December 31, 2017 to December 31, 2018
Issuance of common stock from exercise of stock options
Issuance of common stock from exercise of warrants
Issuance of common stock from vesting of RSUs
Issuance of common stock from 401K match
from December 31, 2016 to December 31, 2017
Issuance of common stock, net of issuance costs
Issuance of common stock from exercise of stock options
Issuance of common stock from exercise of warrants
Issuance of common stock from 401K match
From December 31, 2015 to December 31, 2016
Issuance of common stock from exercise of stock options
Issuance of common stock from exercise of warrants
from December 31, 2014 to December 31, 2015
Conversion of Preferred Stock to Common Stock upon initial public offering
Initial public offering of common stock, net of issuance costs
Issuance of common stock from exercise of stock options
Issuance of common stock from exercise of warrants
from December 31, 2014 to June 30, 2015
Issuance of Series C-2 Preferred Stock, net of issuance costs of $3,782,650
Dividend Series C Preferred Stock
Dividend Series C-1 Preferred Stock
Dividend Series C-2 Preferred Stock